Enteragam Sales Aid 2013

EnteraGam™ acts within the GI tract, not systemically
In the IBS-D study, withdrawal rates due to adverse events were similar among patients taking
EnteraGam™ or placebo9
The most commonly reported adverse events in clinical studies (incidence of 2–5%) included mild
nausea, constipation, stomach cramps, headache, and increased urination
No serious adverse events have been reported to the manufacturer or the FDA
No interactions between EnteraGam™ and commonly prescribed medications have been observed

Important Safety Information: EnteraGam™ contains beef protein; therefore,
patients who have an allergy to beef or any component of EnteraGam™ should
not take this product. The most commonly reported adverse events in clinical
studies (incidence of 2–5%) included mild nausea, constipation, stomach cramps,
headache, and increased urination. Patients who are pregnant or nursing should
not take EnteraGam™, as there are no data regarding the effects of serum-derived
bovine immunoglobulin/protein isolate (SBI) in these populations.

EnteraGam™ does not contain any milk products such as lactose, casein,
or whey. It is gluten-free, dye-free, and soy-free. It contains the following
inactive ingredients: dextrose and sunflower lecithin.

Please see full Prescribing Information including contraindications
in PI section.

In clinical trials…

New EnteraGam™ has demonstrated safety
and tolerability